TY - JOUR
T1 - Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease
AU - Reinhold-Keller, E.
AU - de Groot, K.
AU - Rudert, H.
AU - Nölle, B.
AU - Heller, M.
AU - Gross, W. L.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1996/1
Y1 - 1996/1
N2 - We prospectively studied trimethoprim/sulfamethoxazole (T/S) in inducing remission in 'initial phase' Wegener's granulomatosis (WG), and in sustaining remission in generalized WG, in 72 patients in various disease stages. Nineteen patients with initial phase WC received T/S (2 x 960 mg/day). Another 24 patients with generalized WC received the same dose of T/S (group A) and were compared with 21 patients receiving no further treatment after standard therapy (group B). Eight patients were given T/S plus low-dose prednisone (group C). Eleven of 19 patients (58%) with initial phase WC achieved complete or partial remission lasting a median 43 months (range 6-88 months). Of the remaining eight (42%), five showed local disease progression, and three developed generalized WG. In group A (T/S alone, generalized WC), 10/24 (42%) suffered a relapse after a median 13 months (range 4-58 months). In group B (generalized WG, no further treatment) 29% of patients relapsed after a median 22.5 months (range 18-26 months). All eight patients treated with T/S plus low-dose prednisone (group C) suffered serious relapse after 2-24 months. T/S induced long-term remission in > 50% of patients with initial phase WG; however, neither T/S alone nor T/S plus low-dose prednisone sustained remission in generalized WG.
AB - We prospectively studied trimethoprim/sulfamethoxazole (T/S) in inducing remission in 'initial phase' Wegener's granulomatosis (WG), and in sustaining remission in generalized WG, in 72 patients in various disease stages. Nineteen patients with initial phase WC received T/S (2 x 960 mg/day). Another 24 patients with generalized WC received the same dose of T/S (group A) and were compared with 21 patients receiving no further treatment after standard therapy (group B). Eight patients were given T/S plus low-dose prednisone (group C). Eleven of 19 patients (58%) with initial phase WC achieved complete or partial remission lasting a median 43 months (range 6-88 months). Of the remaining eight (42%), five showed local disease progression, and three developed generalized WG. In group A (T/S alone, generalized WC), 10/24 (42%) suffered a relapse after a median 13 months (range 4-58 months). In group B (generalized WG, no further treatment) 29% of patients relapsed after a median 22.5 months (range 18-26 months). All eight patients treated with T/S plus low-dose prednisone (group C) suffered serious relapse after 2-24 months. T/S induced long-term remission in > 50% of patients with initial phase WG; however, neither T/S alone nor T/S plus low-dose prednisone sustained remission in generalized WG.
UR - http://www.scopus.com/inward/record.url?scp=0030028966&partnerID=8YFLogxK
U2 - 10.1093/oxfordjournals.qjmed.a030133
DO - 10.1093/oxfordjournals.qjmed.a030133
M3 - Journal articles
C2 - 8730339
AN - SCOPUS:0030028966
SN - 0033-5622
VL - 89
SP - 15
EP - 23
JO - QJM - Monthly Journal of the Association of Physicians
JF - QJM - Monthly Journal of the Association of Physicians
IS - 1
ER -